4 / 24
4
2017: A Classical Case of mPDAC
Nab-paclitaxel +
gemcitabine
9
Without 2L therapy: median, 6.2 vs 4.7 mo
With 2L therapy: median 12.8 vs 9.9 mo
And combo regimens >14 months…
Goldstein ASCO-GI 2016 (MPACT trial)
|
|
4 / 24
4 / 24
4
2017: A Classical Case of mPDAC
Nab-paclitaxel +
gemcitabine
9
Without 2L therapy: median, 6.2 vs 4.7 mo
With 2L therapy: median 12.8 vs 9.9 mo
And combo regimens >14 months…
Goldstein ASCO-GI 2016 (MPACT trial)